Definium Therapeutics (NASDAQ:DFTX) Insider Sells $113,257.29 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 3,097 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the transaction, the insider directly owned 359,036 shares of the company’s stock, valued at approximately $13,129,946.52. This represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Down 1.2%

DFTX stock opened at $37.60 on Friday. The company’s 50 day moving average price is $41.15 and its 200 day moving average price is $32.34. The firm has a market capitalization of $5.05 billion, a price-to-earnings ratio of -10.96 and a beta of 2.19. Definium Therapeutics, Inc. has a fifty-two week low of $10.46 and a fifty-two week high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at $138,755,000. Seven Fleet Capital Management LP acquired a new stake in Definium Therapeutics during the 2nd quarter worth $6,992,000. TD Waterhouse Canada Inc. purchased a new stake in Definium Therapeutics in the second quarter valued at $1,592,000. Stableford Capital II LLC purchased a new stake in Definium Therapeutics in the second quarter valued at $1,277,000. Finally, Arizona State Retirement System acquired a new position in Definium Therapeutics in the second quarter valued at $1,431,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Monday, September 14th. Maxim Group set a $55.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $64.88.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.